Tagged with science

Switzerland Although Switzerland is ahead of many of its competitors in Europe on levels of healthcare innovation, one potential stumbling block is access to and use of data. The country’s decentralised healthcare system means that many data sets are siloed and heterogeneous within regions, creating issues in terms of conducting research…

Switzerland A trained physician with several years of practice under her belt, Katharina Gasser then moved into clinical research as an investigator before joining the pharma industry in 2005. Now head of Biogen’s Swiss affiliate and chair of the executive committee of industry association Interpharma, Gasser cites her diverse background as…

Norway Norway has long held a strong international position in neuroscience and is home to Professors May-Britt and Edvard Moser, a married couple and the 2014 winners of the Nobel Prize in Physiology or Medicine. The Mosers, along with their former mentor John O’Keefe, won the award for their work on…

Global COVID-19 has drawn global attention to the sorry state of funding and R&D investment in vaccine development and pandemic prevention, but other previously neglected areas of health research are also now entering the spotlight. One of these underfunded areas is mental health and neurological disorders, leading a global group of…

Switzerland Biogen Switzerland’s Dr Katharina Gasser outlines how the company’s 100 percent commitment to neuroscience helps it to stand apart, why Switzerland will continue to play a vital role in Biogen’s global clinical research footprint, and some of the country’s market access and pricing challenges. Dr Gasser also highlights Biogen’s burgeoning…

Switzerland Switzerland, rightly regarded as one of the world’s most innovative nations, risks damaging its reputation if innovative new medicines continue to face significant delays and roadblocks in their introduction to the domestic Swiss market. Key stakeholders from pharma industry associations Interpharma and scienceindustries and local affiliate heads for multinationals Bayer…

Switzerland scienceindustries’ Stephan Mumenthaler outlines the business-friendly regulation necessary to maintain Swiss life sciences’ competitive edge, how the country’s evolving relationship with the EU stands to impact the industry, and Switzerland’s progress on the road to full digitalisation and Pharma 2.0   What our members want is a good and stable…

Korea Under the stewardship of regenerative medicine industry veteran BG Rhee, Korean firm SCM Lifescience has engaged in several global M&A deals in the past year with the end goal of finding a combination of assets that will bring value to both investors and patients. With a US manufacturing facility now…

South Korea South Korea is the 12th largest healthcare market globally with a market size of around USD 20 billion in 2019. With the government’s plans to invest over USD 1.7 billion in its biopharma and biotech sectors over the next five years, the country’s prominence in the global biopharma landscape will…

USA Barbara Lopez Kunz, CEO of the Drug Information Association (DIA) in the USA, outlines the association’s four key areas of focus – regulatory science, patient engagement, translational science, and value and access – and highlights how it works with stakeholders across the healthcare continuum and across the globe.   Across…

UAE The UAE’s distinctive willingness to embrace innovation and the ‘can-do’ spirit of authorities marks the country out as worthy of attention as an initial product launch platform.   “Along with fellow GCC members, Kuwait and Saudi Arabia, the UAE is notable for its accelerated regulatory pathways. Due to these mechanisms,…

UAE With the corporate objective of having 75 percent of the company’s revenue coming from international markets by 2020, Laboratoires Expanscience is betting on the Middle East and Africa region. Frédéric Le Moigne, managing director for the MEA region, explains the main challenges presented by the political instability affecting the region,…